Market Cap: $11.44M
CI
Cellectar Biosciences, Inc.
CLRB
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $11.44M
Cellectar Biosciences demonstrates significant progress in its cancer treatment initiatives while announcing its recent quarterly financial results. The company reports an earnings per share (EPS) of…
Cellectar Biosciences: Focusing on Advancements in Cancer Therapeutics Cellectar Biosciences stands at a critical juncture as it prepares to release its quarterly earnings report on March 4, 2026. As…
Cellectar Biosciences: Advancements in Cancer Therapeutics Cellectar Biosciences focuses on developing innovative treatment options for cancer, leveraging its proprietary phospholipid ether drug deliv…
Cellectar Biosciences Prepares for Critical Earnings Report Amid Oncology Innovations Cellectar Biosciences is on the brink of releasing its quarterly earnings report on November 13, 2025, a significa…
Cellectar Biosciences Advances Radiopharmaceutical Therapy for Cancer Treatment Cellectar Biosciences, a leader in developing targeted therapies for cancer treatment, is making significant strides wit…
Cellectar Biosciences Advances Cancer Therapy with Proprietary PDC Platform Cellectar Biosciences is at a pivotal moment as it prepares to unveil its quarterly earnings on August 14, 2025. The company…
Cellectar Biosciences Advances Cancer Treatment with PEL Technology Cellectar Biosciences, Inc. is making significant strides in the field of oncology therapeutics, particularly through its proprietar…
Targeted Alpha Therapy: A Paradigm Shift in Cancer Treatment Recent advancements in targeted alpha therapy are revolutionizing the approach to cancer treatment, particularly in the domain of radioimmu…
Cellectar Biosciences: Advancing Targeted Alpha Therapy in Oncology Recent insights into the targeted alpha therapy market, as outlined in a report by ResearchAndMarkets.com, spotlight the transformat…